SAB Biotherapeutics Inc Asset Resilience Ratio
SAB Biotherapeutics Inc asset resilience ratio. SAB Biotherapeutics Inc (SABS) has an Asset Resilience Ratio of 39.61% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can SAB Biotherapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SAB Biotherapeutics Inc (2023–2025)
Asset resilience ratio of SAB Biotherapeutics Inc from 2023 to 2025. This chart shows how SAB Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Read SAB Biotherapeutics Inc (SABS) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SAB Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SABS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $94.36 Million | 39.61% |
| Total Liquid Assets | $94.36 Million | 39.61% |
Asset Resilience Insights
- Very High Liquidity: SAB Biotherapeutics Inc maintains exceptional liquid asset reserves at 39.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SAB Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare SAB Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
SAB Biotherapeutics Inc Asset Resilience Ratio by Year (2023–2025)
SAB Biotherapeutics Inc asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for SAB Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.82% | $86.09 Million | $172.81 Million | +22.98pp |
| 2024-12-31 | 26.84% | $11.86 Million | $44.20 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $83.94 Million | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more